Risks, Unknowns, and Individual Variability Long-term safety data for DSIP are lacking, and its chronic effects on sleep architecture, neuroendocrine function, or cognitive health remain unknown
Beyond T2D and weight management in individuals with overweight or obesity, GLP-1 receptor agonists are approved for metabolic dysfunction associated steatohepatitis in people with moderate or advanced fibrosis, obstructive sleep apnea in obese adults, reduction of major adverse cardiovascular events in adults with T2D and cardiovascular disease (CVD), and slowing progression of chronic kidney disease and cardiovascular mortality in adults with both chronic kidney disease and T2D
Add an Extra Rest Day Most clients on GLP-1 drugs or any diet recover better on a 3-day training split than a 4 or 5-day split
The FDA sent over 50 warning letters in September 2025 to companies doing it anyway
Other Peptide Therapies Besides BPC 157/TB 500, additional peptide therapy is available with Dr
Lower Leg / Calves